 |
Top 100 medical and healthcare startups in USA
Oct 02, 2025 | By Jason Kwon | 19 |
1
Funding: $100M
Ollin is dedicated to advancing novel therapeutic candidates that target a broader spectrum of biology to improve outcomes for patients with severe, vision-threatening conditions.
Ollin is dedicated to advancing novel therapeutic candidates that target a broader spectrum of biology to improve outcomes for patients with severe, vision-threatening conditions.
2
Funding: $435M
Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.
Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.
3
Funding: $172M
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
4
Funding: $64.3M
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
5
Funding: $141M
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
6
Funding: $106.6M
An Immersive Medical Learning Platform. From anatomical representation to procedural planning, zSpace brings a new dimension to medical learning and visualization.
An Immersive Medical Learning Platform. From anatomical representation to procedural planning, zSpace brings a new dimension to medical learning and visualization.
7
Funding: $75.5M
Assort Health provides voice AI agents designed for healthcare call centers, enabling automation of appointment management tasks.
Assort Health provides voice AI agents designed for healthcare call centers, enabling automation of appointment management tasks.
8
Funding: $28M
CellFE is a company developing a microfluidics based device to deliver gene-editing molecules.
CellFE is a company developing a microfluidics based device to deliver gene-editing molecules.
9
Funding: $1.5B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
11
Funding: $1.1B
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
12
Funding: $798.1M
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
13
Funding: $605.6M
Butterfly Network operates at the cutting edge of multiple engineering and scientific disciplines and develops smartphone-connected ultrasound
Butterfly Network operates at the cutting edge of multiple engineering and scientific disciplines and develops smartphone-connected ultrasound
14
Funding: $505.6M
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of their cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.
15
Funding: $505M
Our purpose is to reduce the physical, emotional and economic burdens of obesity as a driver of diseases, creating value for the people we serve and the investors we work for.
Our purpose is to reduce the physical, emotional and economic burdens of obesity as a driver of diseases, creating value for the people we serve and the investors we work for.
16
Funding: $496M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
17
Funding: $353.5M
Beta Bionics is the first medical device company to be doing business as a benefit corporation, and we’re fairly certain that Beta Bionics is the first company to do so in the diabetes space. It develops iLet - a fully integrated bionic pancreas.
Beta Bionics is the first medical device company to be doing business as a benefit corporation, and we’re fairly certain that Beta Bionics is the first company to do so in the diabetes space. It develops iLet - a fully integrated bionic pancreas.
18
Funding: $337M
Exo is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications.
Exo is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications.
19
Funding: $337M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
